Yazar "Erikci, Alev Akyol" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Amifostine Treatment of a Patient with Refractory Acute Myeloid Leukemia
    (Ekin Tibbi Yayincilik Ltd Sti-Ekin Medical Publ, 2009) Tekgunduz, Emre; Erikci, Alev Akyol; Ozturk, Ahmet
    The prognosis for the majority of acute myeloid leukemia (AML) patients without a donor is dismal whether conventional salvage chemotherapy regimens or investigational strategies are used, and most of these patients will eventually die of their disease. There is no standard chemotherapy regimen that provides durable complete remission in patients with refractory AML. Beneficial effects of amifostine, either alone or in combination with conventional chemotherapy, was demonstrated in patients with myelodysplastic syndrome and poor prognosis AML. Here we report our second experience with AML patients who were successfully treated with an amifostine containing noncytotoxic drug combination. The beneficial effects of amifostine are not limited to cytoprotectivity which enables dose-escalation for many chemotherapeutic agents, at least in some refractory AML it can also be used as a bridge to hematopoietic stem cell transplantation.
  • Küçük Resim Yok
    Öğe
    Sticky Platelet Syndrome in Patients with Uninduced Venous Thrombosis
    (Galenos Yayincilik, 2013) Tekgunduz, Emre; Demir, Muzaffer; Erikci, Alev Akyol; Akpinar, Seval; Ozturk, Erman; Kirkizlar, Onur
    Objective: Sticky platelet syndrome (SPS) is a common autosomal dominant inherited platelet disorder. SPS is characterized by platelet hyperreactivity and is associated with arterial and venous thrombosis. The aim of this study was to determine the role of SPS in patients with uninduced venous thrombosis. Material and Methods: The study included 28 patients (15 male and 13 female) with uninduced venous thrombosis. SPS was defined according to Mammen's aggregation method, which is described in detail elsewhere. Results: According to the defined ranges for platelet hyperreactivity, 3 (50%) patients, 2 (33%), and 1 (17%) (n =6 [21%]) with a confirmed diagnosis were classified as type II, I, and III SPS, respectively. In 1 patient SPS was the only hereditary abnormality noted. The other 5 patients carried other inherited coagulation defects, in addition to SPS. Conclusion: The present findings indicate that the prevalence of SPS was 21% in the patients with uninduced venous thrombosis. We therefore suggest that SPS should be considered in the differential diagnosis of such cases.